Drug profile

The FDA adverse-event record for Glucosamine & Chondroitin Sulfate

27 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glucosamine & Chondroitin Sulfate. See the species affected, top reactions, and outcomes below.

27
adverse-event reports
14.8%
death-coded share
Dog
most-reported species
8
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
27
Total Reports
4
Deaths Reported
14.8%
Death Rate

Active Ingredients

Glucosamine & Chondroitin Sulfate

Administration Routes

OralUnknown

Species Affected

Dog 27

Most Affected Breeds

Retriever - Labrador 6
Retriever - Golden 3
Dog (unknown) 2
Mixed (Dog) 1
Terrier - Yorkshire 1
Lhasa Apso 1
Terrier - Jack Russell 1
Shih Tzu 1
Boxer (German Boxer) 1
Terrier - Bull - American Pit 1

Most Reported Reactions

Vomiting 8
Lethargy (see also Central nervous system depression in 'Neurological') 6
Decreased appetite 5
Anorexia 4
Elevated total bilirubin 4
Ataxia 3
Abnormal ultrasound finding 3
Elevated serum alkaline phosphatase (SAP) 3
Elevated liver enzymes 3
Other abnormal test result NOS 3
Drooling 2
Seizure NOS 2

Outcome Breakdown

Ongoing
14 (51.9%)
Outcome Unknown
5 (18.5%)
Recovered/Normal
4 (14.8%)
Euthanized
2 (7.4%)
Died
2 (7.4%)

Glucosamine & Chondroitin Sulfate Adverse Event Insights

27 reports name Glucosamine & Chondroitin Sulfate; 4 recorded a death outcome (14.8% of reported events, not a population-level mortality rate). Active ingredient: Glucosamine & Chondroitin Sulfate. Administration routes: Oral, Unknown.

By species: Dog (27 reports). By breed: Retriever - Labrador (6), Retriever - Golden (3), Dog (unknown) (2).

Leading clinical signs: Vomiting (8), Lethargy (see also Central nervous system depression in 'Neurological') (6), Decreased appetite (5), Anorexia (4). Outcome, 27 coded reports: Ongoing leads at 51.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.